RoundTable Healthcare Partners invests in Polymedco alongside owner-Founders

LAKE FOREST, Ill., June 6, 2024 /PRNewswire/ --RoundTable Healthcare Partners (RoundTable), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today the completion of a majority investment into Polymedco (Polymedco). Terms of the transaction were not disclosed.

Polymedco is a leading marketer and distributor of diagnostic tests primarily used for colorectal cancer (CRC) screening and the diagnosis of cardiac conditions including acute myocardial infarctions. Founded in 1980 and based in Cortlandt Manor, NY, the Company's products are sold to leading distributors, hospital systems, payors, and laboratories across North America.

According to the American Cancer Society, CRC is the second most common cause of cancer deaths in the United States with more than 50,000 deaths annually. The increasing prevalence of colorectal cancer led the U.S. Preventative Services Task Force to recently lower the recommended age for initial CRC screening, including non-invasive fecal immunochemical tests (FIT), to 45 years old. Polymedco's OC-AUTO product line enables high-volume FIT screening for hemoglobin in stool for the early detection of blood that may be associated with colorectal cancer.

We are extremely proud of Polymedco's position as the market leader in FIT screening for colorectal cancer and believe RoundTable is the ideal partner as we transition the business, said Drew Cervasio and Pete Welsh, the co-founders of Polymedco. The firm's core values align with the culture we have built, and RoundTable's deep operating expertise will help Polymedco continue to drive increased awareness of CRC screening and cardiac testing.